Guilin Sanjin Pharmaceutical002275.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Guilin Sanjin Pharmaceutical (002275.SZ) trades at a P/E of 17.70x, P/B of 2.21x, P/S of 3.71x, and a dividend yield of 4.09%.
Longitudinal percentile comparison: P/E sits at the 18th percentile over the trailing 10Y window (vs. 44th percentile over 3Y); P/B sits at the 2nd percentile over the trailing 10Y window (vs. 6th percentile over 3Y); P/S sits at the 8th percentile over the trailing 10Y window (vs. 25th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 16th percentile within its industry and the 20th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.09%, ranking at the 80th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 16.1 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Guilin Sanjin Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 002275 · SZSE: 002275 · 002275
Want the full picture on whether Guilin Sanjin Pharmaceutical (002275.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 17.70 | ||||||
| P/B (MRQ) | 2.21 | ||||||
| P/S (TTM) | 3.71 | ||||||
| Dividend Yield | 4.09% | ||||||
| Buyback + Div Yield | 4.09% |